contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-secured-a-07-meur-agreement-for-the-italian-moli-sani-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Frans-Mikael Rostedt

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Panel Discussion on Health Design 2025 Published, Featuring Teemu Suna.

Here are Luiron’s comments regarding today’s announcement.   Nightingale Health and Terveystalo announced on Tuesday a new strategic agreement that continues and expands the cooperation between the companies, which began in 2021. With the new agreement, Nightingale’s blood analysis technology will be made available to all Terveystalo customer groups, whereas previously it was mainly used in occupational health customers’ health check-ups. The agreement strengthens our view of the commercial value of the company’s technology but does not cause immediate pressure for changes to our forecasts.                   Inderes              Nightingale laajentaa strategista kumppanuuttaan Terveystalon kanssa - Inderes    Uuden sopimuksen myötä Nightingalen verianalyysiteknologia tuodaan kaikkien Terveystalon asiakasryhmien saataville, kun se on aiemmin ollut käytössä lähinnä työterveysasiakkaiden terveystarkastuksissa.

According to the date on Terveystalo’s website, the test would have been available to other consumers, not just occupational health clients, already from May 21, 2025.

nightingalehealth.com              Terveystalo ja Nightingale Health syventävät strategista kumppanuuttaan –...

The Independent – 20 Nov 25              Scientists inch closer to pinprick test to detect diseases decade before...    Findings could help develop early treatment strategies for range of diseases

News and additionally, UK Biobank+Nightingale featured in The Guardian today                   the Guardian – 20 Nov 25              Pinprick blood test could detect disease 10 years before symptoms appear,...    Molecular profiles will give detailed snapshot of person’s physiology and predict diseases from diabetes to cancer and dementia                                               Inderes              Nightingale Health mahdollistaa pääsyn maailman laajimpaan...    Nightingale Health Oyj | Lehdistötiedote | 20.11.2025 klo 10:00:00 EETSairastumisriskien tunnistamisen edelläkävijän ja metabolomiikan globaalisti johtavan toimijan Nightingale Healthin (Nasdaq...

Nightingale Health

The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. 

Translation: Original published in Finnish on 07/07/2025 at 09:03 am EEST
Nightingale <a href="https://www.inderes.se/releases/nightingale-health-selected-as-provider-for-landmark-italian-population-study">was selected</a> as the metabolomics analysis provider for the renowned Moli-sani study in Italy. The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. The agreement is significant for the company&apos;s research business and supports our growth forecasts for the second half of 2025. The company&apos;s revenue from other European countries (including Italy) was some 0.8 MEUR in 2024, making the agreement a significant size in comparison. This is a project-based revenue item, but we believe the agreement is a good additional reference for Nightingale&apos;s technology.
The Moli-sani study, led by INM Neuromed, investigates risk factors associated with major chronic diseases. With Nightingale Health&#x2019;s advanced technology, the study will now examine the impact of nutritional and environmental factors on health.&#xa0;&#xa0; The study also explores biological signatures associated with healthy aging and aims to identify population subgroups with different responses to preventative interventions. Nightingale was selected for the project in accordance with Italian public procurement law, and the parties are now proceeding to finalize the service agreement.

	2024	25e	26e
Revenue	4.4	5.2	8.2
growth-%	4.2 %	19.5 %	57.5 %
EBIT (adj.)	-18.6	-17.3	-16.2
EBIT-% (adj.)	-426.6 %	-331.4 %	-197.6 %
EPS (adj.)	-0.29	-0.27	-0.25
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Nightingale secured a 0.7 MEUR agreement for the Italian Moli-sani study

Key Estimate Figures11.06

Forum discussions